Technical Analysis for PTCT - PTC Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Doji - Bullish? | Reversal | -0.29% | |
| Wide Bands | Range Expansion | -0.29% |
| Alert | Time |
|---|---|
| Possible NR7 | about 7 hours ago |
| Possible Inside Day | about 7 hours ago |
| Down 1% | about 11 hours ago |
| Down 3% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 04/26/2024
PTC Therapeutics, Inc. Description
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Dystrophy Gene Expression Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.75 |
| 52 Week Low | 17.53 |
| Average Volume | 909,613 |
| 200-Day Moving Average | 28.38 |
| 50-Day Moving Average | 29.11 |
| 20-Day Moving Average | 28.76 |
| 10-Day Moving Average | 32.06 |
| Average True Range | 1.61 |
| RSI (14) | 57.08 |
| ADX | 29.9 |
| +DI | 28.97 |
| -DI | 19.23 |
| Chandelier Exit (Long, 3 ATRs) | 30.64 |
| Chandelier Exit (Short, 3 ATRs) | 28.82 |
| Upper Bollinger Bands | 35.72 |
| Lower Bollinger Band | 21.80 |
| Percent B (%b) | 0.66 |
| BandWidth | 48.40 |
| MACD Line | 1.24 |
| MACD Signal Line | 0.90 |
| MACD Histogram | 0.339 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.95 | ||||
| Resistance 3 (R3) | 31.96 | 31.67 | 31.80 | ||
| Resistance 2 (R2) | 31.67 | 31.45 | 31.67 | 31.75 | |
| Resistance 1 (R1) | 31.36 | 31.30 | 31.22 | 31.35 | 31.70 |
| Pivot Point | 31.08 | 31.08 | 31.00 | 31.07 | 31.08 |
| Support 1 (S1) | 30.76 | 30.85 | 30.62 | 30.75 | 30.40 |
| Support 2 (S2) | 30.48 | 30.71 | 30.47 | 30.35 | |
| Support 3 (S3) | 30.17 | 30.48 | 30.30 | ||
| Support 4 (S4) | 30.15 |
